Note 10 – Subsequent Events

 

On January 4, 2016, the Company sold 40,656 shares of common stock for gross proceeds of $130,156 as part of the Sales Agreement with MLV.

 

On January 22, 2016, 500 shares of restricted stock vested and the Company issued 500 shares of common stock to an employee.

 

On January 27, 2016, the Company issued 114,169 shares of common stock for the conversion of 164,580 warrants.

 

On February 16, 2016, the Company entered into a Service agreement with Medpace, Inc. where Medpace agreed to perform Phase 3 study of Iomab-B product. The study is scheduled to be finished in July 2018 with an estimated fees to Medpace of $6.6 million.

 

On February 16, 2016, the Company issued 10,750 shares of common stock to a consultant with a fair value of $19,350.

 

On February 22, 2016, 500 shares of restricted stock vested and the Company issued 500 shares of common stock to an employee.

 

On February 29, 2016 the Company sold 15,946 shares of common stock for gross proceeds of $33,038 as part of the Sales Agreement with MLV.

 

On March 3, 2016, the Company sold 82,557 shares of common stock for gross proceeds of $170,686 as part of the Sales Agreement with MLV.

 

On March 4, 2016, the Company sold 21,109 shares of common stock for gross proceeds of $43,298 as part of the Sales Agreement with MLV.

 

On March 7, 2016, the Company sold 38,369 shares of common stock for gross proceeds of $79,216 as part of the Sales Agreement with MLV.